Management of heart failure with reduced ejection fraction in Europe: design of the ARIADNE registry. (6th February 2020)

• Record Type: Journal Article
• Authors: Zeymer, Uwe; Clark, Andrew L.; Barrios, Vivencio; Damy, Thibaud; Drożdż, Jaroslaw; Fonseca, Candida; Lund, Lars H.; Di Comite, Gabriele; Hupfer, Stephan; Maggioni, Aldo P.
• Is Part Of: ESC heart failure. Volume 7:Number 2(2020)
• Page Start: 727
• Page End: 736
• Publication Date: 2020-02-06
• Subjects: Sacubitril/valsartan -- ARNI -- Heart failure -- Implementation -- Heart failure with reduced ejection fraction -- Real‐life data -- RASI; Heart failure -- Periodicals; 616.129005
• DOI: 10.1002/ehf2.12569
• Languages: English
• ISSNs: 2055-5822

Abstract

Abstract: Aims: The introduction of sacubitril/valsartan (an angiotensin receptor–neprilysin inhibitor) is likely to change the approach to the management of patients with chronic heart failure with reduced ejection fraction (HFrEF). The Assessment of Real Life Care–Describing European Heart Failure Management (ARIADNE) registry will evaluate patient characteristics, practice patterns, outcomes, and healthcare resource utilization in the outpatient setting across Europe, with the main focus on factors that guide physicians' decisions to start and continue sacubitril/valsartan in patients with HFrEF. Methods and results: ARIADNE, a prospective, observational registry will enrol 9000 ambulatory patients with HFrEF in 23 European countries Supplement 1 . The study will describe 4500 patients treated with conventional treatment (including an angiotensin‐converting enzyme inhibitor/angiotensin receptor blocker), and 4500 patients started on sacubitril/valsartan. In each country, patients will be enrolled consecutively over an expected period of 12 months, and followed‐up for 12 months. The primary objective is to describe the baseline clinical and demographic characteristics of patients with chronic HFrEF, which guide the decision of the treating physician to initiate sacubitril/valsartan or to continue conventional treatment. A co‐primary objective is to identify the baseline characteristics that are associated with the likelihood of reaching the target dose of sacubitril/valsartan 97/103 mg twice daily during follow‐up. Conclusions: The ARIADNE registry will provide a comprehensive profile of patients with chronic HFrEF in Europe, will elucidate how management varies between countries, and will help clarify the usage and outcomes associated with use of sacubitril/valsartan in real life.